Properly assessing kinase selectivity is crucial in developing protein kinase inhibitor drugs. However, using comprehensive kinase panel in the early stages can be costly. Axcelead has a solution: the Mini Kinase Panel 46.

We’ve curated 46 essential kinases using AI analysis, reflecting selectivity scores from 320 kinases. This cost-effective option is less than 20% of a comprehensive panel’s cost, perfect for prioritizing chemotypes in early stage of Lead Generation. We also offer a kinase-focused library for inhibitor HTS or phenotypic screening. Contact us to fast-track your protein kinase drug discovery project!